Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5596191 | The American Journal of Pathology | 2016 | 6 Pages |
Abstract
Most melanomas are driven by BRAF(V600E)-activating mutations, while nevi harboring the same mutations have growth arrest. Although decreased p16 expression has been associated with melanoma formation, in recent work, p15 represented a primary effector of oncogene-induced senescence in nevomelanocytes that was diminished in melanomas. This study determined whether decreased p15 levels represent a general biomarker for the transition from nevus to melanoma. We performed p15 and p16 IHC analyses on a random series of nevi and melanomas. Staining was evaluated and graded for percentage and intensity to determine the H score. For real-time quantitative RT-PCR analysis of p15, RNA was extracted from FFPE sections from 14 nevus and melanoma samples via macrodissection. A two-sided t-test was used to evaluate between-group differences in mean H scores and qÎCt values. p15 Expression was significantly increased in melanocytic nevi compared with melanomas (mean H scores, 254.8 versus 132.3; PÂ <Â 0.001). On p15 staining, the H score differential was greater than that with p16 staining [122.5 (PÂ <Â 0.001) and 64.8 (PÂ = 0.055), respectively]. Real-time quantitative RT-PCR analysis revealed a lower mean qÎCt value in melanomas, consistent with lower p15 expression (PÂ = 0.018). Together, these data support the hypothesis that decreased p15 expression is a robust biomarker for distinguishing nevus from melanoma.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Laura A. Taylor, Conor O'Day, Tzvete Dentchev, Kyle Hood, Emily Y. Chu, Todd W. Ridky, John T. Seykora,